Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Volitionrx Ltd (VNRX)

Volitionrx Ltd (VNRX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 194,776
  • Shares Outstanding, K 41,092
  • Annual Sales, $ 0 K
  • Annual Income, $ -18,010 K
  • 60-Month Beta 1.48
  • Price/Sales 9,738.80
  • Price/Cash Flow N/A
  • Price/Book 11.06

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.10
  • Number of Estimates 1
  • High Estimate -0.10
  • Low Estimate -0.10
  • Prior Year -0.11
  • Growth Rate Est. (year over year) +9.09%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.32 +9.72%
on 12/18/19
5.30 -10.57%
on 12/24/19
+0.33 (+7.48%)
since 12/17/19
3-Month
3.81 +24.41%
on 12/05/19
6.20 -23.49%
on 10/21/19
-0.69 (-12.71%)
since 10/17/19
52-Week
2.11 +124.64%
on 01/23/19
6.84 -30.70%
on 09/26/19
+2.45 (+106.99%)
since 01/17/19

Most Recent Stories

More News
Volition Develops a New Improved Nu.Q(TM) Assay Format

VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today provided an update on its Nu Q(TM) Clinical Assays which use a magnetic particle-based assay format. Volition has completely re-engineered its...

VNRX : 4.74 (-1.04%)
VolitionRx Completes Acquisition of Octamer GmbH

VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced the closing of the acquisition of the epigenetic reagent company Octamer GmbH ("Octamer") by its subsidiary Belgian Volition SPRL for...

VNRX : 4.74 (-1.04%)
VolitionRx Limited Announces Strategic Acquisition

VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced an agreement by its subsidiary Belgian Volition SPRL to acquire an epigenetic reagent company, Octamer GmbH ("Octamer"), for approximately...

VNRX : 4.74 (-1.04%)
VolitionRx and Gyros Protein Technologies Awarded an Aggregate $1 million+ Eurostars Cash Grant to Collaborate on Developing a Lung Cancer Blood Test

VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that it was awarded $820,000 (EUR 740,000 Euros) and Gyros Protein Technologies AB, now part of Mesa Laboratories Inc. (NASDAQ:MLAB)...

VNRX : 4.74 (-1.04%)
MLAB : 265.55 (+1.23%)
VolitionRx Limited Announces Proof of Concept Data in Lymphoma and Leukemia

VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced results from its latest proof of concept study. A single pre-clinical Nu.Q(TM) assay utilizing a basic microtiter plate platform detected...

VNRX : 4.74 (-1.04%)
VolitionRx Limited Announces Third Quarter 2019 Financial Results and Business Update

VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced financial results and a business update for the third quarter ended September 30, 2019. Volition management will host a conference...

VNRX : 4.74 (-1.04%)
VolitionRx Limited Announces Third Quarter 2019 Financial Results and Business Update

VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced financial results and a business update for the third quarter ended September 30, 2019. Volition management will host a conference...

VNRX : 4.74 (-1.04%)
VolitionRx Limited Schedules Third Quarter 2019 Earnings Conference Call and Business Update

VolitionRx Limited (NYSE American: VNRX) ("Volition") today announced it will host a conference call on Wednesday, November 13 at 8:30 a.m. Eastern time to discuss its financial and operating results...

VNRX : 4.74 (-1.04%)
Volition announces $500,000 in Non-Dilutive Funding for Volition Veterinary and issues Video

VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced the confirmation of a further $500,000 non-dilutive funding in the form of a loan from the Texas A&M SOFINEX funding agency of the...

VNRX : 4.74 (-1.04%)
Texas A&M University Takes A 12.5% Equity Stake in Volition Veterinary Diagnostics Development LLC

VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") announced today that it (through its subsidiaries) has executed binding agreements contemplated by the previously announced Memorandum of Understanding...

VNRX : 4.74 (-1.04%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Trade VNRX with:

Business Summary

Volition RX Ltd is a life sciences company engaged in developing a range of blood-based epigenetic cancer diagnostic tests. Its tests are designed to detect the nucleosome patterns that are specific to cancer in the blood, and identify some of the major nucleosome varieties that differ between cancer...

See More

Key Turning Points

2nd Resistance Point 4.92
1st Resistance Point 4.83
Last Price 4.74
1st Support Level 4.67
2nd Support Level 4.60

See More

52-Week High 6.84
Fibonacci 61.8% 5.03
Last Price 4.74
Fibonacci 50% 4.47
Fibonacci 38.2% 3.92
52-Week Low 2.11

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar